Hip fracture rates and bisphosphonate consumption in Spain. An ecologic study

European Journal of Clinical Pharmacology

Volumn 69, Issue 3, 2013, Pages 559-564

  Arias, L H Martín ^a   Treceno C ^a   Garcia Ortega P ^a   Rodriguez Paredes J ^a   Escudero, A ^a   Sainz M ^a   Salado, I ^a   Velasco, V ^a   Carvajal, A ^a,b  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Bisphosphonate; Hip fracture; Osteoporosis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CORRELATION COEFFICIENT; DRUG EFFICACY; ECOLOGY; FEMALE; HEALTH CARE POLICY; HIP FRACTURE; HOSPITAL DISCHARGE; HUMAN; LINEAR REGRESSION ANALYSIS; MALE; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SEX DIFFERENCE; SPAIN; TREND STUDY;

AGE DISTRIBUTION; AGE FACTORS; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HIP FRACTURES; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; OSTEOPOROSIS; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; SEX FACTORS; SPAIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84877150052     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1337-z     Document Type: Article

References (33)

1. Cummings-Vaughn LA, Gammack JK (2011) Falls, osteoporosis, and hip fractures. Med Clin North Am 95:495-506
2. Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152:380-390
3. Haleem S, Lutchman L, Mayahi R, Grice JE, Parker MJ (2008) Injury. Mortality following hip fracture: trends and geographical variations over the last 40 years. Injury 39:1157-1163
4. National Statistics Institute (2012) Population in Spain. http://www.ine.es/
5. de Felipe R, Cáceres C, Cimas M, Dávila G, Fernández S, Ruiz T (2010) Clinical characteristics of patients under treatment for osteoporosis in a Primary Care Centre. Who do we treat? Aten Primaria 42:559-563
6. Duarte J, Bolge S, Sen S (2007) An evaluation of patients' preferences for osteoporosis medications and their attributes: the PREFER-International study. Clin Ther 29:488-503
7. Melton LJ 3rd, Kanis JA, Johnell O (2005) Potential impact of osteoporosis treatment on hip fracture trends. J Bone Miner Res 20:895-897
8. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M, American Society for Bone and Mineral Research (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267-2294
9. Morgenstern H (1982) Uses of ecologic analysis in epidemiologic research. Am J Public Health 72:1336-1344
10. http://www.imi-protect.eu/documents/DUinventory-2011-6-WORD97-2003.pdf.
11. Lunde PKM, Baksaas I, Halse M, Strommes B, Aeydvin K (1979) The methodology of drug utilization studies. In: Bergman U, Grimsson A, Wahba AHW, Werterholm B (ed) Studies in drug utilization. WHO Regional Office for Europe, Copenhagen, pp 17-28
12. WHO Collaborating Centre for Drug Statistics Methodology (2007) Complete ATC index. http://www.whocc.no/atcddd/
13. Ministerio de Sanidad, Servicios Sociales e Igualdad (2012) Portal estadístico. http://pestadistico.msc.es/PEMSC25/ArbolNodos.aspx
14. http://www.msc.es/biblioPublic/publicaciones/recursos-propios/infMedic/ docs/vol34n3SubgrATCppiosActivos.pdf. Accesed 1 April 2012
15. http://stat.ethz.ch/R-manual/R-patched/library/stats/html/summary.lm.html
16. http://www.nice.org.uk/. Accesed 1 April 2012
17. Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD, Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE) (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249
18. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541
19. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, for the HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of osteoporosis. N Engl J Med 356:1809-1822
20. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY, for the Hip Intervention Program (HIP) Study Group (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333-340
21. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (1):CD001155
22. Feldstein AC, Weycker D, Nichols GA, Oster G, Rosales G, Boardman DL, Perrin N (2009) Effectiveness of bisphosphonate therapy in a community setting. Bone 44:153-159
23. Erviti J, Timoner J, Alonso A, Gorricho J, López A, Huerta C, Oliva B, Gil M, De Abajo F (2011) Oral bisphosphonates and hip fracture risk in elderly women. Pharmacoepidemiol Drug Saf 20:S28
24. Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305:783-789
25. Schilcher J, Michaëlsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364:1728-1737
26. Sellmeyer DE (2010) Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA 304:480-484
27. Wang Z, Bhattacharyya T (2011) Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996-2007. J Bone Miner Res 26:553-560
28. Fisher A, Martin J, Srikusalanukul W, Davis M (2010) Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary. Clin Interv Aging 5:355-62
29. Hernández JL, Olmos JM, Alonso MA, González- Fernández CR, Martínez J, Pajarón M, Llorca J, González-Macías J (2006) Trend in hip fracture epidemiology over a 14-year period in a Spanish population. Osteoporos Int 17:464-470
30. Guilley E, Chevalley T, Herrmann F, Baccino D, Hoffmeyer P, Rapin CH, Rizzoli R (2008) Reversal of the hip fracture secular trend is related to a decrease in the incidence in institution-dwelling elderly women. Osteoporos Int 19:1741-1747
31. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB (2009) Incidence and mortality of hip fractures in the United States. JAMA 302:1573-1579
32. Abrahamsen B, Vestergaard P (2010) Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997-2006. Osteoporos Int 21:373-830
33. Barba R, Losa JE, Guijarro C, Zapatero A (2006) Reliability of minimal basic data set in the diagnosis of thromboembolic disease. Med Clin 127:255-257